HPV-16 Tied to Improved Survival in Advanced Esophageal Cancer
(HealthDay News) — For patients with advanced-stage esophageal squamous cell carcinoma (ESCC), human papillomavirus (HPV)-16 infection is associated with improved survival and treatment response, according to a study published online February 24 in the Journal of Digestive Diseases.
Wen-Lun Wang, MD, from the E-Da Hospital/I-Shou University in Taiwan, China, and colleagues examined the impact of HPV infection on the prognosis and treatment response of ESCC in a cohort of 150 patients. The presence and subtype of HPV-DNA in tumor specimens was assessed by polymerase chain reaction and sequencing.
Eighteen percent of ESCC tumor samples were HPV-positive, of which 81.5% were positive for HPV-16 infection. The researchers observed no difference between HPV-positive and HPV-negative groups in terms of the prevalence of developing multiple ESCC (29.6 and 28.5%, respectively; P=0.90). Survival was significantly better for patients with HPV-16 positive advanced-stage ESCC compared with HPV-negative disease (three-year survival, 55 vs. 21%; log-rank P=0.03), in subgroup analysis. The presence of HPV-16 correlated with a significant decrease in the mortality rate (hazard ratio, 0.41). Chemoradiation response was better for patients with vs. those without HPV-16 infection (P=0.026).
"In patients with advanced stage ESCC, HPV-16 positive patients had a significantly favorable survival, especially for those who receiving chemoradiation therapy," the authors write.